IP Library Granted Patent US 10,752,658
Granted Patent B2
US 10,752,658 · App. 15/762,092 · Granted Aug 25, 2020

OmpG variants

Inventors: Cynthia Cech (Mountain View, CA); Tim Craig (Mountain View, CA); Christos Tzitzilonis (Mountain View, CA); Alexander Yang (Mountain View, CA); Liv Jensen (Mountain View, CA); Charlotte Yang (Mountain View, CA); Corissa Harris (Mountain View, CA); Matthew DiPietro (Gilroy, CA); Dhruti Dalal (Sunnyvale, CA)
Assignee: ROCHE SEQUENCING SOLUTIONS, INC.
C07K14/245C12N9/1252C12Q1/68C12Q1/6874C12Y207/07007G01N33/6803C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,752,658
App. No.
15/762,092
Granted
Aug 25, 2020
Kind
B2
Abstract

The present disclosure provides variant OmpG polypeptides, compositions comprising the OmpG variant polypeptides, and methods for using the variant OmpG polypeptides as nanopores for determining the sequence of single stranded nucleic acids. The variant OmpG nanopores reduce the ionic current noise versus the parental OmpG polypeptide from which they are derived and thereby enable sequencing of polynucleotides with single nucleotide resolution. The reduced ionic current noise also provides for the use of these OmpG nanopore variants in other single molecule sensing applications, e.g., protein sequencing.

Claims (18)

1. An isolated OmpG variant comprising an amino acid sequence having at least 95% sequence identity to residues 1-268 of the amino acid sequence set forth as SEQ ID NO: 5, the variant comprising a deletion of one or more loop-6 amino acids, a deletion of amino acid D215 of SEQ ID NO: 5, and an A217 amino acid residue of SEQ ID NO: 5, and wherein the variant retains the ability to form a nanopore.

2. The isolated OmpG variant of claim 1 , further comprising a mutation of one or more of amino acids R211, E15, R68, Y50, E152, E174, E17, D215, K114, E174, F66, or E31 of SEQ ID NO: 5.

3. The isolated OmpG variant of claim 2 , wherein the mutation comprises one or more of a R211N, R68N, Y50K, Y50N, or E17K mutation of SEQ ID NO: 5.

4. The isolated OmpG variant of claim 3 , wherein the mutation of SEQ ID NO: 5 is a Y50K amino acid substitution.

5. The isolated OmpG variant of claim 1 , wherein the OmpG variant is operably linked to a SpyTag construct.

6. The isolated OmpG variant of claim 5 , wherein the OmpG variant and the operably linked SpyTag construct comprise an amino acid sequence having at least 95% sequence identity to the amino acid sequence set forth as SEQ ID NO:10 or SEQ ID NO:11.

7. The isolated OmpG variant of claim 5 , further comprising a polymerase, wherein the polymerase is operably linked to the OmpG variant via the SpyTag construct.

8. The isolated OmpG variant of claim 1 , wherein the variant comprises a deletion corresponding to each of amino acids 216-227 of SEQ ID NO:2.

9. An isolated OmpG variant comprising an amino acid sequence having at least 95% sequence identity to residues 1-268 of the amino acid sequence set forth as SEQ ID NO:5, the variant comprising one or more loop-6 amino acid deletions, a Y50K amino acid substitution of SEQ ID NO: 5, and an A217 amino acid residue of SEQ ID NO: 5, and wherein the variant retains the ability to form a nanopore.

10. The isolated OmpG variant of claim 9 , further comprising a mutation of one or more of amino acids R211, E15, R68, E152, E174, E17, D215, K114, E174, F66, or E31 of SEQ ID NO:2.

11. The isolated OmpG variant of claim 10 , wherein the mutation is a D215 deletion of SEQ ID NO: 5.

12. The isolated OmpG variant of claim 10 , wherein the mutation comprises one or more of a R211N or R68N mutations of SEQ ID NO: 5.

13. The isolated OmpG variant of claim 9 , wherein the variant is operably linked to a SpyTag construct.

14. The isolated OmpG variant of claim 13 , wherein a polymerase is operably linked to the OmpG variant via the SpyTag construct.

15. The isolated OmpG variant of claim 13 , wherein the OmpG variant and the operably linked SpyTag construct comprise an amino acid sequence having at least 95% sequence identity to the amino acid sequence set forth as SEQ ID NO:6.

16. The isolated OmpG variant of claim 9 , wherein the variant comprises a deletion of each amino acid corresponding to amino acid residues 216-227 of SEQ ID NO:2.

17. The isolated OmpG variant of claim 1 , wherein the variant comprises an amino acid sequence having at least 98% sequence identity to residues 1-268 of the amino acid sequence set forth as SEQ ID NO: 5.

18. The isolated OmpG variant of claim 9 , wherein the variant comprises an amino acid sequence having at least 98% sequence identity to residues 1-268 of the amino acid sequence set forth as SEQ ID NO: 6.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2020
From: CECH, CYNTHIA; CRAIG, TIMOTHY KELLOGG; DALAL, DHRUTI; DIPIETRO, MATTHEW; HARRIS, CORISSA JUNE; JENSEN, LIV ELISABETH; TZITZILONIS, CHRISTOS; YANG, ALEXANDER HYUNMIN; YANG, CHARLOTTE LING
To: ROCHE SEQUENCING SOLUTIONS, INC.
Reel/Frame 052194/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2020
From: ROCHE SEQUENCING SOLUTIONS, INC.
To: GENIA TECHNOLOGIES, INC.
Reel/Frame 052195/0146 →
MERGER Recorded Mar 23, 2020
From: GENIA TECHNOLOGIES, INC.
To: ROCHE SEQUENCING SOLUTIONS, INC.
Reel/Frame 052195/0404 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2020
From: CECH, CYNTHIA
To: GENIA TECHNOLOGIES, INC.
Reel/Frame 051941/0266 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2020
From: CRAIG, TIMOTHY KELLOGG; DALAL, DHRUTI; DIPIETRO, MATTHEW; HARRIS, CORISSA JUNE; JENSEN, LIV ELISABETH; TZITZILONIS, CHRISTOS; YANG, ALEXANDER HYUNMIN; YANG, CHARLOTTE LING
To: GENIA TECHNOLOGIES, INC.
Reel/Frame 051941/0374 →
MERGER AND CHANGE OF NAME Recorded Feb 26, 2020
From: GENIA TECHNOLOGIES, INC.; ROCHE SEQUENCING SOLUTIONS, INC.
To: ROCHE SEQUENCING SOLUTIONS, INC.
Reel/Frame 051941/0403 →
Continuity (3)
Provisional Application 62222197 · Sep 22, 2015
Provisional Application 62333672 · May 9, 2016
Related Publication 20180362594A1 · Dec 20, 2018
Cited By (1)
US 12,435,114